Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Capital Expenditures (2018 - 2025)

Historic Capital Expenditures for Precision Biosciences (DTIL) over the last 8 years, with Q2 2025 value amounting to $2000.0.

  • Precision Biosciences' Capital Expenditures fell 9285.71% to $2000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $163000.0, marking a year-over-year increase of 2834.65%. This contributed to the annual value of $250000.0 for FY2024, which is 8722.53% down from last year.
  • Per Precision Biosciences' latest filing, its Capital Expenditures stood at $2000.0 for Q2 2025, which was down 9285.71% from $64000.0 recorded in Q1 2025.
  • Precision Biosciences' 5-year Capital Expenditures high stood at $1.7 million for Q2 2021, and its period low was -$26000.0 during Q4 2023.
  • For the 5-year period, Precision Biosciences' Capital Expenditures averaged around $591388.9, with its median value being $576500.0 (2022).
  • Its Capital Expenditures has fluctuated over the past 5 years, first crashed by 10411.39% in 2023, then soared by 47307.69% in 2024.
  • Precision Biosciences' Capital Expenditures (Quarter) stood at $1.5 million in 2021, then plummeted by 58.01% to $632000.0 in 2022, then plummeted by 104.11% to -$26000.0 in 2023, then skyrocketed by 473.08% to $97000.0 in 2024, then crashed by 97.94% to $2000.0 in 2025.
  • Its Capital Expenditures stands at $2000.0 for Q2 2025, versus $64000.0 for Q1 2025 and $97000.0 for Q4 2024.